Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Quantification of speech and synchrony in the conversation of adults with autism spectrum disorder.

Ochi K, Ono N, Owada K, Kojima M, Kuroda M, Sagayama S, Yamasue H.

PLoS One. 2019 Dec 5;14(12):e0225377. doi: 10.1371/journal.pone.0225377. eCollection 2019. Erratum in: PLoS One. 2020 Jan 17;15(1):e0227387.

2.

White matter microstructural alterations across four major psychiatric disorders: mega-analysis study in 2937 individuals.

Koshiyama D, Fukunaga M, Okada N, Morita K, Nemoto K, Usui K, Yamamori H, Yasuda Y, Fujimoto M, Kudo N, Azechi H, Watanabe Y, Hashimoto N, Narita H, Kusumi I, Ohi K, Shimada T, Kataoka Y, Yamamoto M, Ozaki N, Okada G, Okamoto Y, Harada K, Matsuo K, Yamasue H, Abe O, Hashimoto R, Takahashi T, Hori T, Nakataki M, Onitsuka T, Holleran L, Jahanshad N, van Erp TGM, Turner J, Donohoe G, Thompson PM, Kasai K, Hashimoto R; COCORO.

Mol Psychiatry. 2019 Nov 29. doi: 10.1038/s41380-019-0553-7. [Epub ahead of print]

PMID:
31780770
3.

Differentiation of schizophrenia using structural MRI with consideration of scanner differences: A real-world multisite study.

Nemoto K, Shimokawa T, Fukunaga M, Yamashita F, Tamura M, Yamamori H, Yasuda Y, Azechi H, Kudo N, Watanabe Y, Kido M, Takahashi T, Koike S, Okada N, Hirano Y, Onitsuka T, Yamasue H, Suzuki M, Kasai K, Hashimoto R, Arai T.

Psychiatry Clin Neurosci. 2020 Jan;74(1):56-63. doi: 10.1111/pcn.12934. Epub 2019 Nov 4.

4.
5.

Alterations in serotonin transporter and body image-related cognition in anorexia nervosa.

Yokokura M, Terada T, Bunai T, Nakaizumi K, Kato Y, Yoshikawa E, Futatsubashi M, Suzuki K, Yamasue H, Ouchi Y.

Neuroimage Clin. 2019;23:101928. doi: 10.1016/j.nicl.2019.101928. Epub 2019 Jul 3.

6.

Paternal age contribution to brain white matter aberrations in autism spectrum disorder.

Yassin W, Kojima M, Owada K, Kuwabara H, Gonoi W, Aoki Y, Takao H, Natsubori T, Iwashiro N, Kasai K, Kano Y, Abe O, Yamasue H.

Psychiatry Clin Neurosci. 2019 Oct;73(10):649-659. doi: 10.1111/pcn.12909. Epub 2019 Jul 30.

PMID:
31271249
7.

Quantitative facial expression analysis revealed the efficacy and time course of oxytocin in autism.

Owada K, Okada T, Munesue T, Kuroda M, Fujioka T, Uno Y, Matsumoto K, Kuwabara H, Mori D, Okamoto Y, Yoshimura Y, Kawakubo Y, Arioka Y, Kojima M, Yuhi T, Yassin W, Kushima I, Benner S, Ogawa N, Kawano N, Eriguchi Y, Uemura Y, Yamamoto M, Kano Y, Kasai K, Higashida H, Ozaki N, Kosaka H, Yamasue H.

Brain. 2019 Jul 1;142(7):2127-2136. doi: 10.1093/brain/awz126.

PMID:
31096266
8.

Emerging pharmacological therapies in fragile X syndrome and autism.

Yamasue H, Aran A, Berry-Kravis E.

Curr Opin Neurol. 2019 Aug;32(4):635-640. doi: 10.1097/WCO.0000000000000703.

PMID:
31045620
9.

Aberrant attentive and inattentive brain activity to auditory negative words, and its relation to persecutory delusion in patients with schizophrenia.

Iwashiro N, Takano Y, Natsubori T, Aoki Y, Yahata N, Gonoi W, Kunimatsu A, Abe O, Kasai K, Yamasue H.

Neuropsychiatr Dis Treat. 2019 Feb 14;15:491-502. doi: 10.2147/NDT.S194353. eCollection 2019.

10.

Social Interaction Improved by Oxytocin in the Subclass of Autism with Comorbid Intellectual Disabilities.

Higashida H, Munesue T, Kosaka H, Yamasue H, Yokoyama S, Kikuchi M.

Diseases. 2019 Feb 22;7(1). pii: E24. doi: 10.3390/diseases7010024. Review.

11.

Acute agranulocytosis when switching from risperidone to paliperidone.

Wakuda T, Suzuki A, Hasegawa M, Ichikawa D, Yamasue H.

Aust N Z J Psychiatry. 2019 Jun;53(6):586-587. doi: 10.1177/0004867418821441. Epub 2019 Jan 14. No abstract available.

PMID:
30636434
12.

Culture and cannabinoid receptor gene polymorphism interact to influence the perception of happiness.

Matsunaga M, Masuda T, Ishii K, Ohtsubo Y, Noguchi Y, Ochi M, Yamasue H.

PLoS One. 2018 Dec 21;13(12):e0209552. doi: 10.1371/journal.pone.0209552. eCollection 2018.

13.

Neurochemical evidence for differential effects of acute and repeated oxytocin administration.

Benner S, Aoki Y, Watanabe T, Endo N, Abe O, Kuroda M, Kuwabara H, Kawakubo Y, Takao H, Kunimatsu A, Kasai K, Bito H, Kakeyama M, Yamasue H.

Mol Psychiatry. 2018 Sep 27. doi: 10.1038/s41380-018-0249-4. [Epub ahead of print]

PMID:
30262887
14.

Comparative Analyses of Copy-Number Variation in Autism Spectrum Disorder and Schizophrenia Reveal Etiological Overlap and Biological Insights.

Kushima I, Aleksic B, Nakatochi M, Shimamura T, Okada T, Uno Y, Morikawa M, Ishizuka K, Shiino T, Kimura H, Arioka Y, Yoshimi A, Takasaki Y, Yu Y, Nakamura Y, Yamamoto M, Iidaka T, Iritani S, Inada T, Ogawa N, Shishido E, Torii Y, Kawano N, Omura Y, Yoshikawa T, Uchiyama T, Yamamoto T, Ikeda M, Hashimoto R, Yamamori H, Yasuda Y, Someya T, Watanabe Y, Egawa J, Nunokawa A, Itokawa M, Arai M, Miyashita M, Kobori A, Suzuki M, Takahashi T, Usami M, Kodaira M, Watanabe K, Sasaki T, Kuwabara H, Tochigi M, Nishimura F, Yamasue H, Eriguchi Y, Benner S, Kojima M, Yassin W, Munesue T, Yokoyama S, Kimura R, Funabiki Y, Kosaka H, Ishitobi M, Ohmori T, Numata S, Yoshikawa T, Toyota T, Yamakawa K, Suzuki T, Inoue Y, Nakaoka K, Goto YI, Inagaki M, Hashimoto N, Kusumi I, Son S, Murai T, Ikegame T, Okada N, Kasai K, Kunimoto S, Mori D, Iwata N, Ozaki N.

Cell Rep. 2018 Sep 11;24(11):2838-2856. doi: 10.1016/j.celrep.2018.08.022.

15.

Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial.

Yamasue H, Okada T, Munesue T, Kuroda M, Fujioka T, Uno Y, Matsumoto K, Kuwabara H, Mori D, Okamoto Y, Yoshimura Y, Kawakubo Y, Arioka Y, Kojima M, Yuhi T, Owada K, Yassin W, Kushima I, Benner S, Ogawa N, Eriguchi Y, Kawano N, Uemura Y, Yamamoto M, Kano Y, Kasai K, Higashida H, Ozaki N, Kosaka H.

Mol Psychiatry. 2018 Jun 29. doi: 10.1038/s41380-018-0097-2. [Epub ahead of print]

PMID:
29955161
16.

Neuroanatomical Correlates of Advanced Paternal and Maternal Age at Birth in Autism Spectrum Disorder.

Kojima M, Yassin W, Owada K, Aoki Y, Kuwabara H, Natsubori T, Iwashiro N, Gonoi W, Takao H, Kasai K, Abe O, Kano Y, Yamasue H.

Cereb Cortex. 2019 Jun 1;29(6):2524-2532. doi: 10.1093/cercor/bhy122.

PMID:
29800092
17.

Surface morphology of the orbitofrontal cortex in individuals at risk of psychosis: a multicenter study.

Nakamura M, Takahashi T, Takayanagi Y, Sasabayashi D, Katagiri N, Sakuma A, Obara C, Koike S, Yamasue H, Furuichi A, Kido M, Nishikawa Y, Noguchi K, Matsumoto K, Mizuno M, Kasai K, Suzuki M.

Eur Arch Psychiatry Clin Neurosci. 2019 Jun;269(4):397-406. doi: 10.1007/s00406-018-0890-6. Epub 2018 Mar 23.

PMID:
29572660
18.

Neural and Genetic Correlates of the Social Sharing of Happiness.

Matsunaga M, Kawamichi H, Umemura T, Hori R, Shibata E, Kobayashi F, Suzuki K, Ishii K, Ohtsubo Y, Noguchi Y, Ochi M, Yamasue H, Ohira H.

Front Neurosci. 2017 Dec 19;11:718. doi: 10.3389/fnins.2017.00718. eCollection 2017.

19.

Computer-analyzed facial expression as a surrogate marker for autism spectrum social core symptoms.

Owada K, Kojima M, Yassin W, Kuroda M, Kawakubo Y, Kuwabara H, Kano Y, Yamasue H.

PLoS One. 2018 Jan 2;13(1):e0190442. doi: 10.1371/journal.pone.0190442. eCollection 2018.

20.

The effect of duration of illness and antipsychotics on subcortical volumes in schizophrenia: Analysis of 778 subjects.

Hashimoto N, Ito YM, Okada N, Yamamori H, Yasuda Y, Fujimoto M, Kudo N, Takemura A, Son S, Narita H, Yamamoto M, Tha KK, Katsuki A, Ohi K, Yamashita F, Koike S, Takahashi T, Nemoto K, Fukunaga M, Onitsuka T, Watanabe Y, Yamasue H, Suzuki M, Kasai K, Kusumi I, Hashimoto R; COCORO.

Neuroimage Clin. 2017 Nov 8;17:563-569. doi: 10.1016/j.nicl.2017.11.004. eCollection 2018.

21.

Clinical potential of oxytocin in autism spectrum disorder: current issues and future perspectives.

Benner S, Yamasue H.

Behav Pharmacol. 2018 Feb;29(1):1-12. doi: 10.1097/FBP.0000000000000341. Review.

PMID:
28857771
22.

Oxytocin and Autism Spectrum Disorders.

Yamasue H, Domes G.

Curr Top Behav Neurosci. 2018;35:449-465. doi: 10.1007/7854_2017_24. Review.

PMID:
28766270
23.

Increased Occipital Gyrification and Development of Psychotic Disorders in Individuals With an At-Risk Mental State: A Multicenter Study.

Sasabayashi D, Takayanagi Y, Takahashi T, Koike S, Yamasue H, Katagiri N, Sakuma A, Obara C, Nakamura M, Furuichi A, Kido M, Nishikawa Y, Noguchi K, Matsumoto K, Mizuno M, Kasai K, Suzuki M.

Biol Psychiatry. 2017 Nov 15;82(10):737-745. doi: 10.1016/j.biopsych.2017.05.018. Epub 2017 Jul 11.

PMID:
28709499
24.

Association between salivary serotonin and the social sharing of happiness.

Matsunaga M, Ishii K, Ohtsubo Y, Noguchi Y, Ochi M, Yamasue H.

PLoS One. 2017 Jul 6;12(7):e0180391. doi: 10.1371/journal.pone.0180391. eCollection 2017.

25.

[Voxel-Based Morphometry in Autism Spectrum Disorder].

Yamasue H.

Brain Nerve. 2017 May;69(5):529-538. doi: 10.11477/mf.1416200779. Review. Japanese.

PMID:
28479530
26.

Neural basis for inferring false beliefs and social emotions in others among individuals with schizophrenia and those at ultra-high risk for psychosis.

Takano Y, Aoki Y, Yahata N, Kawakubo Y, Inoue H, Iwashiro N, Natsubori T, Koike S, Gonoi W, Sasaki H, Takao H, Kasai K, Yamasue H.

Psychiatry Res Neuroimaging. 2017 Jan 30;259:34-41. doi: 10.1016/j.pscychresns.2016.11.003. Epub 2016 Nov 23.

PMID:
27960147
27.

Oxytocin receptor gene variations predict neural and behavioral response to oxytocin in autism.

Watanabe T, Otowa T, Abe O, Kuwabara H, Aoki Y, Natsubori T, Takao H, Kakiuchi C, Kondo K, Ikeda M, Iwata N, Kasai K, Sasaki T, Yamasue H.

Soc Cogn Affect Neurosci. 2017 Mar 1;12(3):496-506. doi: 10.1093/scan/nsw150.

28.

Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial.

Kosaka H, Okamoto Y, Munesue T, Yamasue H, Inohara K, Fujioka T, Anme T, Orisaka M, Ishitobi M, Jung M, Fujisawa TX, Tanaka S, Arai S, Asano M, Saito DN, Sadato N, Tomoda A, Omori M, Sato M, Okazawa H, Higashida H, Wada Y.

Transl Psychiatry. 2016 Aug 23;6(8):e872. doi: 10.1038/tp.2016.152.

29.

Letter to the editor; A corrigendum with respect to our research article entitled "Association between impaired brain activity and volume at the sub-region of Broca's area in ultra-high risk and first-episode schizophrenia: A multi-modal neuroimaging study".

Iwashiro N, Koike S, Satomura Y, Suga M, Nagai T, Natsubori T, Tada M, Gonoi W, Takizawa R, Kunimatsu A, Yamasue H, Kasai K.

Schizophr Res. 2016 Oct;176(2-3):578-579. doi: 10.1016/j.schres.2016.05.026. Epub 2016 Jun 6. No abstract available.

PMID:
27283452
30.

Association between impaired brain activity and volume at the sub-region of Broca's area in ultra-high risk and first-episode schizophrenia: A multi-modal neuroimaging study.

Iwashiro N, Koike S, Satomura Y, Suga M, Nagai T, Natsubori T, Tada M, Gonoi W, Takizawa R, Kunimatsu A, Yamasue H, Kasai K.

Schizophr Res. 2016 Apr;172(1-3):9-15. doi: 10.1016/j.schres.2016.02.005. Epub 2016 Feb 9. Erratum in: Schizophr Res. 2016 Oct;176(2-3):578-579.

PMID:
26873807
31.

Abnormal asymmetries in subcortical brain volume in schizophrenia.

Okada N, Fukunaga M, Yamashita F, Koshiyama D, Yamamori H, Ohi K, Yasuda Y, Fujimoto M, Watanabe Y, Yahata N, Nemoto K, Hibar DP, van Erp TG, Fujino H, Isobe M, Isomura S, Natsubori T, Narita H, Hashimoto N, Miyata J, Koike S, Takahashi T, Yamasue H, Matsuo K, Onitsuka T, Iidaka T, Kawasaki Y, Yoshimura R, Watanabe Y, Suzuki M, Turner JA, Takeda M, Thompson PM, Ozaki N, Kasai K, Hashimoto R.

Mol Psychiatry. 2016 Oct;21(10):1460-6. doi: 10.1038/mp.2015.209. Epub 2016 Jan 19.

32.

Head Motion and Correction Methods in Resting-state Functional MRI.

Goto M, Abe O, Miyati T, Yamasue H, Gomi T, Takeda T.

Magn Reson Med Sci. 2016;15(2):178-86. doi: 10.2463/mrms.rev.2015-0060. Epub 2015 Dec 22. Review.

33.

Promising evidence and remaining issues regarding the clinical application of oxytocin in autism spectrum disorders.

Yamasue H.

Psychiatry Clin Neurosci. 2016 Feb;70(2):89-99. doi: 10.1111/pcn.12364. Epub 2015 Oct 16. Review.

34.

Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism.

Watanabe T, Kuroda M, Kuwabara H, Aoki Y, Iwashiro N, Tatsunobu N, Takao H, Nippashi Y, Kawakubo Y, Kunimatsu A, Kasai K, Yamasue H.

Brain. 2015 Nov;138(Pt 11):3400-12. doi: 10.1093/brain/awv249. Epub 2015 Sep 3.

PMID:
26336909
35.

A Neuroanatomical Signature for Schizophrenia Across Different Ethnic Groups.

Gong Q, Dazzan P, Scarpazza C, Kasai K, Hu X, Marques TR, Iwashiro N, Huang X, Murray RM, Koike S, David AS, Yamasue H, Lui S, Mechelli A.

Schizophr Bull. 2015 Nov;41(6):1266-75. doi: 10.1093/schbul/sbv109. Epub 2015 Aug 11.

36.

Neuroimaging-Aided Prediction of the Effect of Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder: A Randomized Controlled Trial.

Ishii-Takahashi A, Takizawa R, Nishimura Y, Kawakubo Y, Hamada K, Okuhata S, Kawasaki S, Kuwabara H, Shimada T, Todokoro A, Igarashi T, Watanabe K, Yamasue H, Kato N, Kasai K, Kano Y.

Neuropsychopharmacology. 2015 Nov;40(12):2852. doi: 10.1038/npp.2015.154. Epub 2015 Jul 8. No abstract available.

37.

Using endophenotypes to examine molecules related to candidate genes as novel therapeutics: The "endophenotype-associated surrogate endpoint (EASE)" concept.

Yamasue H.

Neurosci Res. 2015 Oct;99:1-7. doi: 10.1016/j.neures.2015.05.007. Epub 2015 Jun 6. Review.

PMID:
26055442
38.

Neuroimaging-Aided Prediction of the Effect of Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder: A Randomized Controlled Trial.

Ishii-Takahashi A, Takizawa R, Nishimura Y, Kawakubo Y, Hamada K, Okuhata S, Kawasaki S, Kuwabara H, Shimada T, Todokoro A, Igarashi T, Watanabe K, Yamasue H, Kato N, Kasai K, Kano Y.

Neuropsychopharmacology. 2015 Nov;40(12):2676-85. doi: 10.1038/npp.2015.128. Epub 2015 May 4. Erratum in: Neuropsychopharmacology. 2015 Nov;40(12):2852.

39.

Reply: Does imitation act as an oxytocin nebulizer in autism spectrum disorder?

Aoki Y, Yamasue H.

Brain. 2015 Jul;138(Pt 7):e361. doi: 10.1093/brain/awv061. Epub 2015 Mar 11. No abstract available.

PMID:
25762464
40.

Common variants at 1p36 are associated with superior frontal gyrus volume.

Hashimoto R, Ikeda M, Yamashita F, Ohi K, Yamamori H, Yasuda Y, Fujimoto M, Fukunaga M, Nemoto K, Takahashi T, Tochigi M, Onitsuka T, Yamasue H, Matsuo K, Iidaka T, Iwata N, Suzuki M, Takeda M, Kasai K, Ozaki N.

Transl Psychiatry. 2014 Oct 21;4:e472. doi: 10.1038/tp.2014.110.

41.

Oxytocin improves behavioural and neural deficits in inferring others' social emotions in autism.

Aoki Y, Yahata N, Watanabe T, Takano Y, Kawakubo Y, Kuwabara H, Iwashiro N, Natsubori T, Inoue H, Suga M, Takao H, Sasaki H, Gonoi W, Kunimatsu A, Kasai K, Yamasue H.

Brain. 2014 Nov;137(Pt 11):3073-86. doi: 10.1093/brain/awu231. Epub 2014 Aug 22.

PMID:
25149412
42.

Oxytocin's neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: a randomized controlled trial.

Aoki Y, Watanabe T, Abe O, Kuwabara H, Yahata N, Takano Y, Iwashiro N, Natsubori T, Takao H, Kawakubo Y, Kasai K, Yamasue H.

Mol Psychiatry. 2015 Apr;20(4):447-53. doi: 10.1038/mp.2014.74. Epub 2014 Jul 29.

43.

An fMRI study of visual lexical decision in patients with schizophrenia and clinical high-risk individuals.

Natsubori T, Hashimoto R, Yahata N, Inoue H, Takano Y, Iwashiro N, Koike S, Gonoi W, Sasaki H, Takao H, Abe O, Kasai K, Yamasue H.

Schizophr Res. 2014 Aug;157(1-3):218-24. doi: 10.1016/j.schres.2014.05.027. Epub 2014 Jun 2.

PMID:
24893907
44.

A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study.

Koike S, Bundo M, Iwamoto K, Suga M, Kuwabara H, Ohashi Y, Shinoda K, Takano Y, Iwashiro N, Satomura Y, Nagai T, Natsubori T, Tada M, Yamasue H, Kasai K.

Transl Psychiatry. 2014 Apr 8;4:e379. doi: 10.1038/tp.2014.19.

45.

Two distinct neural mechanisms underlying indirect reciprocity.

Watanabe T, Takezawa M, Nakawake Y, Kunimatsu A, Yamasue H, Nakamura M, Miyashita Y, Masuda N.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):3990-5. doi: 10.1073/pnas.1318570111. Epub 2014 Mar 3.

46.

Aberrant interference of auditory negative words on attention in patients with schizophrenia.

Iwashiro N, Yahata N, Kawamuro Y, Kasai K, Yamasue H.

PLoS One. 2013 Dec 23;8(12):e83201. doi: 10.1371/journal.pone.0083201. eCollection 2013.

47.

Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: a randomized trial.

Watanabe T, Abe O, Kuwabara H, Yahata N, Takano Y, Iwashiro N, Natsubori T, Aoki Y, Takao H, Kawakubo Y, Kamio Y, Kato N, Miyashita Y, Kasai K, Yamasue H.

JAMA Psychiatry. 2014 Feb;71(2):166-75. doi: 10.1001/jamapsychiatry.2013.3181.

PMID:
24352377
48.

Prefrontal activation during inhibitory control measured by near-infrared spectroscopy for differentiating between autism spectrum disorders and attention deficit hyperactivity disorder in adults.

Ishii-Takahashi A, Takizawa R, Nishimura Y, Kawakubo Y, Kuwabara H, Matsubayashi J, Hamada K, Okuhata S, Yahata N, Igarashi T, Kawasaki S, Yamasue H, Kato N, Kasai K, Kano Y.

Neuroimage Clin. 2013 Oct 26;4:53-63. doi: 10.1016/j.nicl.2013.10.002. eCollection 2014.

49.

Altered metabolites in the plasma of autism spectrum disorder: a capillary electrophoresis time-of-flight mass spectroscopy study.

Kuwabara H, Yamasue H, Koike S, Inoue H, Kawakubo Y, Kuroda M, Takano Y, Iwashiro N, Natsubori T, Aoki Y, Kano Y, Kasai K.

PLoS One. 2013 Sep 18;8(9):e73814. doi: 10.1371/journal.pone.0073814. eCollection 2013.

50.

Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.

Natsubori T, Inoue H, Abe O, Takano Y, Iwashiro N, Aoki Y, Koike S, Yahata N, Katsura M, Gonoi W, Sasaki H, Takao H, Kasai K, Yamasue H.

Schizophr Bull. 2014 Sep;40(5):1128-39. doi: 10.1093/schbul/sbt124. Epub 2013 Sep 10.

Supplemental Content

Loading ...
Support Center